Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.
2 reports, 2 independent
Updated Aug 18
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Scribe Therapeutics received Overweight and Outperform ratings from Wells Fargo and Leerink Partners following its IPO.1 source
Scribe Therapeutics IPO led by Leerink; Eli Lilly and a16z are major shareholders.1 source
Keep exploring
The entities involved
-
Scribe Therapeutics
genetic medicine therapeutics company from Alameda, California
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
-
Leerink partners
U.S. investment bank
Related events
Coverage
Newest first; wire copies grouped- cnbc.com
- livemint.comEli Lilly-backed Scribe Therapeutics climbs 67% after raising $128.7 million in an upsized IPO | Stock Market News